Skip to main content

The TODAY2 study

Presenter: Kimberly Drews, PhD; Lorraine E. Levitt Katz, MD; Petter Bjornstad, MD; Neil H. White, MD; Jeanie B. Tryggestad, MD; Ruth S. Weinstock, MD, PhD.

Saturday 8 June: 13:45–15:45

Conference coverage direct to your inbox

The TODAY study found that metformin produced “durable” glycemic control in only approximately half of children aged 10–17 years given the medication to combat type 2 diabetes. The addition of rosiglitazone significantly improved glycemic outcomes, but intensive lifestyle intervention did not.

At ADA, the investigators will report the longer-term disease course in the TODAY participants who signed up for the observational follow-up study, TODAY2. Based on accumulating evidence, the team is anticipating rapid diabetes progression and the development of complications.

More on this trial

Back to the conference hub